<DOC>
	<DOCNO>NCT00185965</DOCNO>
	<brief_summary>Brief summary TBD</brief_summary>
	<brief_title>CPG 7909 + Local Radiotherapy Recurrent Low-Grade Lymphomas</brief_title>
	<detailed_description>This single institution phase 1-2 trial evaluate safety , feasibility efficacy CpG injection ( 4 intratumoral injection follow 6 peri-tumoral injection ) combine local irradiation patient recurrent low-grade lymphoma . Patients receive low-dose radiotherapy single tumor site day 1 2 ( 2 Gy day ) . CpG injection administer tumor site within 24 hour 24 hour radiation , day 8 15 . Weekly dos CpG administer subcutaneously region previous injection 6 additional dos .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<criteria>Patients must meet follow criterion order eligible entry trial . Biopsy confirm lowgrade Bcell lymphoma initial stage mycosis fungoides stage IBIVA . Bcell lymphoma patient must fail least one prior treatment . Mycosis fungoides patient must fail intolerant least 2 topical one systemic treatment . Patients must least one site disease accessible intratumoral injection CpG percutaneously Tumor specimen must available immunological study either previous biopsy new biopsy obtain initiation treatment . Patients must measurable disease injection site biopsy site . 18 year age old Karnofsky Performance Status ( KPS ) &gt; 70 . Adequate bone marrow function : WBC &gt; 4,000uL , hemoglobin &gt; 10g/dL ; platelet count &gt; 100,000/mm3 ; ANC &gt; 1000 . Adequate hepatic function : bilirubin &lt; = 1.5 mg/dL ; SGOT/SGPT &lt; 3xupper limit normal Adequate renal function : serum creatinine &lt; = 2.0mg/dL . Required wash period prior therapy : Topical therapy : 2 week Chemotherapy : 4 week Radiotherapy ( include photo therapy ) : 4 week Systemic biological therapy mycosis fungoides : 4 week Other investigational therapy : 4weeks Rituximab : 12 week Patients reproductive potential partner must agree use effective ( &gt; 90 % reliability ) form contraception study 4 week follow last study drug administration . Women reproductive potential must negative urine pregnancy test . Life expectancy great 4 month . Able comply treatment schedule . A patient may enrol trial follow criterion meet . Preexisting autoimmune antibody mediate disease include : systemic lupus , erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia , exclude control thyroid disease , presence autoantibody without clinical autoimmune disease . Known history human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C ( active , prior treatment , ) . Patients active infection fever &gt; 38.50 C within three day prior first schedule treatment . CNS metastases Prior malignancy ( active within 5 year screen ) except basal cell completely excise noninvasive squamous cell carcinoma skin , situ squamous cell carcinoma cervix . History allergic reaction attribute compound similar composition CpG 7909 Current anticoagulant therapy ( ASA &lt; = 325mg/day allow ) . Significant cardiovascular disease ( i.e . NYHA class 3 congestive heart failure ; myocardial infarction past 6 month ; unstable angina ; coronary angioplasty past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia ) . Pregnant lactating . Any medical history , include laboratory result , deem investigator likely interfere participation study , interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>non-Hodgkin</keyword>
	<keyword>lymphoma</keyword>
	<keyword>mycosis</keyword>
	<keyword>fungoides</keyword>
</DOC>